Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

75.4%

49 terminated/withdrawn out of 65 trials

Success Rate

21.0%

-65.5% vs industry average

Late-Stage Pipeline

3 trials in Phase 3/4

Results Transparency

223%

29 of 13 completed trials have results

Key Signals

29 with results39 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 2

62(95.4%)

Phase 3

3(4.6%)

65Total

Phase 2(62)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials

NCT02864888Phase 3Not Yet Recruiting

Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma

Role: lead

NCT02742883Phase 2Suspended

A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)

Role: lead

NCT02887040Phase 3Not Yet Recruiting

Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma

Role: lead

NCT00003468Phase 2Completed

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

Role: lead

NCT00003458Phase 2Completed

Antineoplaston Therapy in Treating Children With Brain Tumors

Role: lead

NCT00003479Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Ependymoma

Role: lead

NCT00003511Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Multiple Myeloma

Role: lead

NCT00003487Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Role: lead

NCT00003508Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Role: lead

NCT00003498Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Role: lead

NCT00003531Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

Role: lead

NCT00003509Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Role: lead

NCT00003526Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

Role: lead

NCT00003492Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Role: lead

NCT00003499Phase 2Completed

Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Role: lead

NCT00003453Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Role: lead

NCT00003474Phase 2Completed

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

Role: lead

NCT00003456Phase 2Completed

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

Role: lead

NCT00003471Phase 2Terminated

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Role: lead

NCT00003535Phase 2Terminated

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

Role: lead